MCAS Protocol Stack: VIP (10mg) / ARA-290 (2mg) / KPV (10mg) / TA-1 (5mg)
ImmunityDescription
The mcas protocol stack combines four immune-modulating peptides that address mast cell activation syndrome (mcas) and cirs (chronic inflammatory response syndrome) through four distinct, non-overlapping mechanisms. vip (vasoactive intestinal peptide) acts as the primary mast cell degranulation suppressor — binding vpac1/vpac2 receptors on mast cells and immune cells to reduce histamine release, reduce pro-inflammatory cytokines (il-6, tnf-alpha) by up to 40%, and modulate the mast cell response without broadly suppressing immune function. vip also synchronizes the suprachiasmatic nucleus for circadian rhythm regulation relevant to immune cycling. ara-290 (cibinetide) adds neuroprotective and tissue-repair signaling via the innate repair receptor (irr) — particularly relevant for the small fiber neuropathy (sfn) that is commonly comorbid with mcas, addressing the neurological component of mast cell-driven tissue damage. kpv (melanocortin tripeptide from alpha-msh) provides targeted mucosal anti-inflammatory signaling via mc1r and mc3r, reducing gut and skin inflammation driven by mast cell degranulation products. ta-1 (thymosin alpha-1) normalizes t-regulatory (treg) cell populations — restoring the immune calibration that prevents the hyperactive immune responses driving mcas chronicity. the four mechanisms collectively address mast cell activity (vip), neuroprotection (ara-290), mucosal anti-inflammation (kpv), and t-regulatory normalization (ta-1) — the most complete peptide-based mcas research protocol available. for research and educational purposes only. consult a qualified healthcare professional.
Specifications
| Amount in Vial | sold as 4-part immune protocol |
|---|---|
| BAC Water | see individual peptide entries |
| Amount per Unit | see individual entries |
| Recommended Dose | see individual peptide entries for precise dosing |
| Frequency | Vip daily intranasal; ara-290 daily subcutaneous; kpv daily subcutaneous; ta-1 2x per week subcutaneous |
| Injection Type | Intranasal (vip) + subcutaneous (ara-290, kpv, ta-1) |
| Timing | Week 1: Begin VIP alone, titrating from 50mcg intranasal twice daily — establish mast cell stabilization baseline before adding other components. Week 2+: Add ARA-290 100-200mcg SubQ morning and KPV 200-500mcg SubQ daily. Week 3+: Add TA-1 1.5mg SubQ twice weekly. This staged introduction allows identification of individual compound tolerability. See individual entries (VIP, KPV, TA-1) for full reconstitution and dosing. Ongoing monitoring of symptom load recommended throughout. |
Dose Calculator
Based on see individual entries (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: sold as 4-part immune protocol
Add BAC water: see individual peptide entries
Concentration: see individual entries
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.